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SYNOPSIS: In an attempt to clarify the effect of amantadine hydrochloride therapy in Parkinson's disease, dopa metabolites were
measured in the urine of 15 patients who were taking this medication. The results indicated that patients on amantadine therapy

had lower urinary levels of epinephrine plus norepinephrine than
either normal individuals or parkinsonian patients not receiving
amantadine. Patients who developed livedo reticularis during
amantadine therapy showed a small but significant increase in
urinary dopamine levels and a similar decrease in dopac levels,
when compared to other patients on amantadine who did not
develop livedo reticularis.

Since Schwab and colleagues ( 1969) have reported on
the use of amantadine hydrochloride in the treatment of
Parkinson's disease the drug has been investigated by many
others, most of whom have found it useful. Unlike the many
biochemical studies done on parkinsonian patients on levodopa therapy, little has been reported on biochemical changes
in the serum, spinal fluid and urine of patients treated with
amantadine hydrochloride. The action of this drug is not well
understood at present but there are several theories as to its
possible mode of action. Grelak and associates ( 1970) suggested that the mechanism of action of amantadine may be
by the release of catecholamines from storage sites. Parkes
et al. (1971) indicated that the mode of action of amantadine remains undetermined but they demonstrated that it
does not increase the low cerebrospinal fluid homovanillic
acid concentrations of patients with Parkinson's disease.
Amantadine hydrochloride has little or no anticholinergic action, but will release catecholamines from storage sites in
peripheral nerves and myocardium ( 1969). Scatton et al.
( 1970) demonstrated that amantadine increased the synthesis of dopamine in the striatum of the rat, also increased the
release of dopamine from the striatal dopaminergic terminals
in this animal. Livedo reticularis is a well-known side effect
associated with amantadine therapy in parkinsonian patients.
This condition probably results from peripheral arterial constriction; there is some evidence that amantadine may release
dopamine or some other dopa metabolite ( 1971). In an attempt to clarify the effect of amantadine hydrochloride in
Parkinson's disease, dopa metabolites were measured in the
urine of patients who were taking this medication. Particular
attention was paid to those who developed livedo reticularis.

double-blind double-crossover study in which the patients alternately received either placebo or amantadine hydrochloride. At the end of the two week period of administration of
placebo or amantadine hydrochloride a 24-hour urine specimen was collected. Twenty-four-hour specimens were also
collected from seven patients who developed livedo reticularis in their extremities while undergoing amantadine therapy; these specimens were collected both during the height
of symptoms and later after amantadine had been discontinued for at least two weeks and the symptoms of livedo
reticularis had been absent for at least one week. For both
groups of patients at least one urine determination was made
while the patient was on amantadine and one urine determination while either on no medication or on placebo. The urine
was evaluated for epinephrine, norepinephrine, dopamine,
dopa, dopac, and homovanillic acid. These compounds were
separated from the urine and from each other by passing an
aliquot of each specimen through a series of three different
ion-exchange columns. Catecholamines (epinephrine, norepinephrine and dopamine) were retained on a cation exchange column. These compounds were eluted with a boric
acid solution and quantitatively measured by a fluorimetric
analysis. Catechol acids ( dopac and homovanillic acid) present in the effluent from the cation exchange column were
retained on an anion exchange column. An aliquot of 0.lM
NaCl eluate of the anion exchange column was used for a
colorimetric determination of dopac. The colorimetric determination of dopa was carried out on an aliquot of the effluent from the anion exchange column. A second aliquot of
the O.lM NaCl eluate from this column was passed over an
alumina column which retained all of the acidic metabolites
except homovanillic acid. The homovanillic acid in the effluent of the alumina column was then subjected to fluorimetric
analysis. The ion-exchange column separation scheme and
the detailed quantitative methodology is being reported in
a separate communication ( 1971).
Normal values have been established in this laboratory as
follows: epinephrine plus norepinephrine: 0.04 to 0.08 p.g/
ml; dopac: 2-5 p.g/ml; dopamine: 0.2 to 0.3 p.g/ml; and
dopa: less than 2.0 µ.g/ml.

MATERIALS AND METHODS

Ten patients with Parkinson's disease were evaluated in a

l Departments of Neurology and Biochemistry, University of
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RESULTS

A total of 15 patients were evaluate:! for urine dopa metabolites. All 15 were grouped together; these data were
evaluated and compared with respect to the patients being
on and off medication and as to whether they did or did not
develop livedo reticularis.
It was found that the range of values of the metabolites in
normal individuals was too broad to detect meaningful increases or decreases in these substances in the urine specimens from patients. In general, patients with Parkinson's
disease exhibited elevated levels of dopac, dopamine, and
dopa in their urine. Patients on amantadine therapy excreted
lower levels of epinephrine plus norepinephrine than normal
individuals. When patients who developed livedo reticularis
were compared with those who did not develop symptoms,
no changes in the excretion of the metabolites were observed.
Homovanillic acid excretion was similar in patients and normal individuals.

CATECHOLAMINE METABOLITES IN URINE
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In a further attempt to assess the data, the values of the
excreted metabolites from the fifteen patients were subjected
to statistical analysis. The mean value of each metabolite was
calculated and compared for patients on placebo as well as
for patients on amantadine hydrochloride therapy. Means or
averages are plotted with confidence intervals on graphs in
Figure 1, for four of the measured urine catecholamines and
separated into non-livedo and livedo patients. The norepinephrine plus epinephrine values differed significantly between
the placebo and the amantadine data, indicating less norepinephrine plus epinephrine in the urine of patients while
on amantadine HCl (using a "p" value less than 0.01). This
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can be seen in the graph for norepinephrine plus epinephrine.
The patients were also grouped into those who did and who
did not develop livedo reticularis while on amantadine. From
the graph no significant difference is noted for the epinephrine plus norepinephrine or dopa in these comparisons. The
most significant difference is noted in the means for dopac,
where patients who devebped livedo reticularis while on
amantadine had a significant decrease in the level of dopac
0.05). Also, there was a decrease
in the urine ("p" value
of dopac in the urine of all livedo reticularis patients whether
they were on or off amantadine; this also is significant at the
5 percent level. Patients with livedo reticularis on or off
amantadine had higher levels of dopamine ("p" value
0.05).

=

=

CONCLUSIONS

The results indicate that patients receivmg amantadine
hydrochloride excreted less norepinephrine plus epinephrine
in the urine than when they were not taking the drug. The
livedo reticularis patients either on or off the medication excreted less dopac and more dopamine as compared to the
non-livedo reticularis patients.
From the above data there is no direct evidence of the
release of catecholamines by amantadine hydrochloride as
measured in the urine. On the other hand, there is less norepinephrine and epineph1ine in the urine during amantadine
administration. The significance of the decreased dopac and
the increased dopamine levels in the urine in patients who
develop livedo reticularis is unknown. Patients who did develop livedo reticularis had a lower creatinine clearance than
patients who did not develop the skin disorder. In the parkinsonian patient one might postulate amantadine hydrochloride increases the physiological availability of dopamine by
increasing the synthesis of and/ or release of dopamine in or
from the dopaminergic neurons and thus enhances its effectiveness as a neurotransmitter. This would be consistent with
the finding of decreased levels of end metabolites such as
norepinephrine and epinephrine. This increased synthesis
and/ or increased release of dopamine by amantadine hydrochloride has been demonstrated by Scatton and associates
( 1970). One hypothesis for the increased synthesis of dopamine would be some physiological enhancement or increased
synthesis of tyrosine hydroxylase ( 1971). From our data there
is little or no supp:Jrt for the concept that amantadine hydrochloride acts to block a metabolic pathway especially from
dopamine to dopac or dopamine to norepinephrine, since no
elevated levels of dopamine were detectable in the urine
when the patient was receiving amantadine. Amantadine
hydrochloride also probably does not act as a false neurotransmitter, since we have some data to support the concept
that there is a change in the metabolic pathways because of
decreased epinephrine and norepinephrine in the urines of
patients receiving amantadine. This theory would also explain the development of livedo reticularis since dopamine
is a vasoconstrictor, acts on alpha receptors and could produce vasoconstriction in the arteriole of the anatomical cone
in the skin to result in a central ischemic area with the peripheral vasodilation. This is the typical fishnet-like appearance of livedo reticularis. Further studies need to be carried
out on dopa metabolites in the urine, spinal fluid and serum
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in patients rece1vmg amantadine, using proper controls, especially in patients who do not develop livedo reticularis.
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